Objective To provide a consistently updated overview of the comparative effectiveness of treatments for Achilles tendinopathy.
Design Living systematic review and network meta-analysis.
Data sources Multiple databases including grey literature sources were searched up to February 2019.
Study eligibility criteria Randomised controlled trials examining the effectiveness of any treatment in patients with both insertional and/or midportion Achilles tendinopathy. We excluded trials with 10 or fewer participants per treatment arm or trials investigating tendon ruptures.
Data extraction and synthesis Reviewers independently extracted data and assessed the risk of bias. We used the Grading of Recommendations Assessment, Development and Evaluation to appraise the certainty of evidence.
Primary outcome measure The validated patient-reported Victorian Institute of Sport Assessment-Achilles questionnaire.
Results 29 trials investigating 42 different treatments were included. 22 trials (76%) were at high risk of bias and 7 (24%) had some concerns. Most trials included patients with midportion tendinopathy (86%). Any treatment class seemed superior to wait-and-see for midportion Achilles tendinopathy at 3 months (very low to low certainty of evidence). At 12 months, exercise therapy, exercise+injection therapy and exercise+night splint therapy were all comparable with injection therapy for midportion tendinopathy (very low to low certainty). No network meta-analysis could be performed for insertional Achilles tendinopathy.
Summary/conclusion In our living network meta-analysis no trials were at low risk of bias and there was large uncertainty in the comparative estimates. For midportion Achilles tendinopathy, wait-and-see is not recommended as all active treatments seemed superior at 3-month follow-up. There seems to be no clinically relevant difference in effectiveness between different active treatments at either 3-month or 12-month follow-up. As exercise therapy is easy to prescribe, can be of low cost and has few harms, clinicians could consider starting treatment with a calf-muscle exercise programme.
PROSPERO registration number CRD42018086467.
- Achilles tendon
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @ArcoVlist, @marinuswinters, @clare_ardern, @rj_devos
Contributors MW, AW and R-JV came up with the study idea. ACV, MW, AW, CLA, NJW, DMC, JANV and R-JV were involved in designing the study. ACV and R-JV performed the literature search and screened trials for inclusion. ACV, MW, AW, CLA and R-JV performed the risk of bias assessment and data extraction. MW, NJW and DMC designed the statistical analysis plan and analysed the data. ACV, MW, AW and R-JV interpreted the results of the data analyses. ACV, MW, AW and R-JV drafted the manuscript. R-JV is the study guarantor. All authors reviewed the final manuscript and agreed to be accountable for all aspects of the work and approved the final manuscript for submission. The corresponding author attests that all listed authors meet the authorship criteria and that no others meeting the criteria have been omitted.
Funding This research received a grant from the Dutch Association of Medical Specialists to develop a clinical guideline for the treatment of patients with Achilles tendinopathy. The Dutch Patient Federation is involved in this guideline development and assisted in sending out patient surveys.
Competing interests NJW led a research project in collaboration with Pfizer (project ended 31 December 2018). Pfizer part-funded a junior researcher. The projects were purely methodological, using historical data on pharmacological treatments for pain relief.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.